They still see the expensive drug as experimental. Medicare, however, has said it will cover the drug for most of its patients.
in which the drug slowed memory and thinking decline by about five months in those who got the treatment compared with those who got a dummy drug. Some Alzheimer’s experts say the delay is likely too subtle for patients or their families to notice.
Highmark and the North Carolina plan say they are still monitoring Leqembi and could re-evaluate their decision. Prominent insurers that will cover the drug for commercial plans include Kaiser Permanente and Elevance Health, the largest provider of Blue Cross-Blue Shield plans in the United States. A spokesman for another big health insurer, UnitedHealthcare, declined to comment when contacted by AP.
Chambers said they have found that the decision to not cover a drug largely happens when the evidence supporting the drug is considered questionable.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Popular Scripps doctor groups said to have 'terminated' Medicare Advantage contractsScripps says it remains in negotiations with plans, insists that no decisions have been made
Lire la suite »
Seeking Medicare coverage for weight loss drugs, pharma giant courts Black influencers - New York Amsterdam NewsPharmaceutical giant Novo Nordisk has turned to influential Black Americans in pursuit of what would be a lucrative victory.
Lire la suite »
AARP calls out the 25 most costly Medicare Part D drugs ahead of price negotiationsAARP is singling out the 25 most costly drugs under Medicare Part D plans as the government prepares to being negotiating prices with drug companies.
Lire la suite »
Judge ‘permanently’ blocks Medicare Advantage switch for 250K NYC retirees, city to appealRetirees had protested the planned transition, saying it was a potential obstacle to accessing certain medical providers and treatments that also left the door open for increased costs.
Lire la suite »
Rothman Orthopaedics’ decision to drop Medicare bundled payments shows why it’s so hard to slow rising health costsRothman Orthopaedic was among the early adopters of Medicare’s so-called bundled payments, but now it only has them with private insurers. It shows the challenges of altering a health-care payment system that has been built on the back of Medicare.
Lire la suite »
Guiding an Improved Dementia Experience (GUIDE) Model | CMS Innovation CenterOn July 31, 2023, the Centers for Medicare & Medicaid Services (CMS) announced a new voluntary nationwide model – the Guiding an Improved Dementia Experience (GUIDE) Model – a model test that aims to support people living with dementia and their unpaid caregivers. CMS is accepting letters of interest for the GUIDE Model through September 15, 2023, and will release a GUIDE Request for Applications (RFA) for the model in Fall 2023. The model will launch on July 1, 2024, and run for eight years.
Lire la suite »